Table 4.

The influence of RC timing on clinical outcomes

Author, year	Number of patients*	Mean time from initial diagnosis to RC	Established maximal time interval	Percentage of patients operated within maximal time interval	Mean follow–up	Consequences of exceeding maximal time interval
Gore et al. 2009 [8]	441	n.a.	12 weeks	n.a.	n.a.	Increased risk of disease–specific mortality in 2–year follow–up – HR 7.7
Lee et al. 2006 [9]	214	61 days	93 days	87.9%	40 months	Higher overall mortality – 54% vs. 39% Higher disease–specific mortality – 35% vs. 25% No effect on the risk of non–organ confined disease
May et al. 2004 [10]	189	1.8 months	3 months	77.8%	40 months	Higher rate of T4 disease – 31 vs. 14% Decreased 5–year overall survival – 26% vs. 54% Decreased 5–year progression–free survival – 34% vs. 55%
Chang et al. 2003 [11]	153	63 days	90 days	87.6%	–	Higher rate of stage T3 or higher – 81% vs. 52%
Sanchez–Ortis et al. 2003 [12]	189	7.9 weeks	12 weeks	89.9%	36 months	Higher rate of extravesical (T3 or T4 and/or N + ) disease – 84% vs. 42.8% Decreased 3–year overall survival – 34.9% vs. 62.1%
Hara et al. 2002 [13]	50	2.65 months	3 months	56%	50.8 months	Reduced 5–year recurrence–free survival – 52.5% vs. 86.9% Reduced 5–year overall survival – 47.3% vs. 80.3% Increased risk of vascular involvement – 73% vs. 46% No effect on the risk of non–organ confined disease

^*Papers cited in table covers only MIBC cases